


Survey of IGNITE Graduates

OMB # 0925-0766, Exp. 04/2023

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0766). Do not return the completed form to this address.

1. What was your IGNITE grant number or title? 

2. Has your IGNITE-funded project received additional funding? (check all that apply) 

- Received NIH funding
- Attracted private investments
- Received non-profit grant or contract
- No additional funding
- Other (please specify)

3. If no follow-on funding has been achieved, have you applied for other funding? (check all that apply) 🗨 0

Applied for an NIH grant or contract

Had discussions with private investors

Applied for non-profit grant or contract

Other (please describe below)

No, but another application is being planned (please tell us what funding you are considering)

No, more data is needed before the next stage of funding

No, this project won't be pursued further (please tell us why)

Please describe

4. In addition to direct follow-on funding for your IGNITE-funded project, did the IGNITE support facilitate other funding indirectly? (For example, the IGNITE-supported therapeutic is now being pursued for a different indication or tools/models developed are being applied to a new project.) (please describe) 🗨 0

5. Aside from publications and patents (which NIH already has data on), were there advancements in the field supported by the IGNITE-funded project you'd like to tell us about? (please describe)

6. Would you recommend changes to the scope of the IGNITE program? Were there things you needed to do but were out of scope?

7. We see a lot of no-cost extensions requested prior to the milestone review. This was true even before the pandemic. If you needed more time for phase 1, please tell us why. If you didn't, please let us know what allowed you to complete phase 1 on time. (please describe)

8. Is 3 years enough time for the scope of the IGNITE FOA you applied under?

9. Are there changes we could make to the program to help projects advance more quickly to the next stage? (please describe)

10. Is there other feedback you'd like to share?

Done